Someone at the Receptor Life Sciences in Seattle got the jump on everyone in the cannabis industry and started developing an inhaler containing CBD in a dry powder format.
Imagine you are medicating with the click of a index finger, taking a deep breath and holding your breath – just to exhale and leave no trace of scent.
This method of medication may become a reality if the combination of powder and inhaler passes Food and Drug Administration Phase 1b clinical trials as it tests the efficacy and safety of the product. (Both the compound and the company’s inhaler are components of an inhaled insulin product that the FDA reportedly already approves.)
The product is called RLS103: It is an inhalation powder that contains “synthetic CBD and FDKP, an FDA-approved inhalation aid,” it says on the company’s website. “In an initial proof-of-concept pharmacokinetic clinical study, RLS103 produced immediate CBD absorption at maximum concentration less than 4 minutes after inhalation.”
In other words, “they look at the bioavailability of [synthetic] CBD and how it is absorbed or absorbed into the body, “explained David Fowler of the Marijuana Industry Trade Association (MITA) in Phoenix.
The FDA process, one would think, is similar to that when testing the CBD-infused powder used in edible goods, but it is different since an inhaler is included in the finished product.
Fowler, who co-founded MITA in 2015 and is the CEO of the Cannaval Music Festival, which takes place on April 30 in Phoenix, is giving up the new concept of medication through a therapeutic-oral remedy – a green thumb.
“People generally would much rather inhale something than smoke and or have to eat something and wait for the results,” he continued. “So I could imagine it would affect the market, especially when this delivery method comes on the market.”
The competing product “has the potential to be the first in its class to treat acute anxiety disorders,” Receptor Life Sciences CEO and President Mark Theeuwes said in a statement. He added that the data would hopefully guide future studies for other neurological and psychiatric disorders.
Last month, the Seattle-based drug company raised $ 9.7 million to promote the cannabidiol-based therapeutic candidate for acute anxiety through clinical trials. This process was not their first time as they have previously developed therapies for “diseases of the central nervous system using FDA-approved drug delivery technologies”.
If approved, the new concept of medication could cut into the edible CBD market.
“Edible products tend to take much longer to be effective and are much more challenging to regulate dosage,” Fowler continued. “People’s bodies tend to ingest and absorb CBD or any other compound for that matter, differently. So while inhaling, the compounds go directly into the lungs and into the bloodstream with a very high bioavailability, in the same way. as smoking in relation to eating an edible, you immediately feel the effects of the product. ”